Natera Class Action Lawsuit NTRA | Deadline June 27, 2022

Natera Class Action Lawsuit

Natera is facing a class action lawsuit (Natera Class Action Lawsuit) alleging that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s non-invasive prenatal test, Panorama, was not reliable and resulted in high rates of false positives; (2) the Company’s screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; (3) as a result of defendants’ false and misleading claims about Natera’s technology, the Company was exposed to substantial legal and regulatory risks; (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and (5) as a result of the foregoing, defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis.

If you incurred a loss on NTRA common stock purchased between February 26, 2020 and April 19, 2022, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Western District of Texas, and our firm is reaching out to investors to discuss their legal rights.

If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.

You only have until June 27, 2022 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.

Natera Class Action

NEW YORK, June 15, 2022 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP, a renowned national investor rights law firm, reminds shareholders of the deadline for submitting a lead plaintiff motion in a securities class action lawsuit that has been brought on behalf of shareholders who bought or acquired Natera, Inc. common stock (referred to as “Natera” or the “Company”) (NASDAQ: NTRA) between February 26, 2020 and April 19, 2022, inclusive (the ” The action, which asserts violations of the Securities Exchange Act of 1934, was filed in the United States District Court for the Western District of Texas.

Natera Lawsuit

In the areas of oncology, organ health, and women’s health, Natera provides genetic testing. Throughout the Class Period, Defendants repeatedly assured investors that Panorama was dependable, that Prospera was more accurate than competing tests, and that Natera’s growth was fueled by its superior technology and customer experience. The Company produces and markets, among other things, a non-invasive prenatal test (“NIPT”) called “Panorama” and a screening test for kidney transplant failure called “Prospera.”

NTRA Class Action Lawsuit

According to the complaint, the defendants misrepresented the following facts and/or concealed others: (1) the Company’s non-invasive prenatal test, Panorama, was unreliable and had a high rate of false positives; (2) the Company’s screening test for kidney transplant failure, Prospera, did not have superior precision compared to competing tests; and (3) as a result of defendants’ false and misleading claims about Natera’s technology, the Company was exposed to significant legal risk.

NTRA Class Action

Located in Austin, Texas, Natera is a Delaware firm that provides genetic testing for women’s health, oncology, and organ health. The Company, among other things, manufactures and markets a non-invasive prenatal test (NIPT) called “Panorama” and a screening test for kidney transplant failure called “Prospera.” Throughout the Class Period, Defendants repeatedly assured investors that Panorama was trustworthy, that Prospera was more accurate than competing tests, and that Natera’s growth was fueled by its superior technology and customer experience.

NTRA Lawsuit

Before the market opened on March 9, 2022, Hindenburg Research released a brief report in which it claimed that “Natera’s revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers,” among other potential problems at the prenatal testing company. On March 9, 2022, shares of Natera, Inc. fell more than 15% in premarket trading. Then, on March 15, 2022, prior to the market opening, CareDX, Inc. declared that it had prevailed in its lawsuit against Natera for fraudulent advertising. On March 15, 2022, premarket trading of Natera, Inc. stock decreased 12% in response to this news.

NTRA stock

A diagnostics business called Natera, Inc. is involved in the research, creation, and marketing of genetic testing products. It offers non-invasive paternity testing, the Panorama non-invasive prenatal test (NIPT), Vistara, Horizon carrier screening (HCS), Spectrum pre-implantation genetic screening, and Spectrum pre-implantation genetic diagnosis (PAT). Constellation is a cloud-based software product that the company also sells, giving laboratory users access to the algorithms and bioinformatics needed to validate and run experiments based on the technology. The business is situated in Austin, Texas, and was started by Matthew Rabinowitz and Jonathan Sheena in November 2003.